PMDA posts statement on impaired leaflet mobility after TAVI valve deployment
「関係団体からのお知らせ」に「TAVI弁展開後における弁尖可動不良事象に関するステートメント」を掲載しました
Published: 2025-12-18 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2025-12-18, the Pharmaceuticals and Medical Devices Agency (PMDA) announced that it had posted a statement on impaired leaflet mobility after TAVI valve deployment in its notices from related organizations section. The title identifies the statement's subject but does not provide its findings or recommendations.
Business Impact
Healthcare professionals performing transcatheter aortic valve implantation (TAVI) may find the statement relevant because it concerns impaired leaflet mobility after valve deployment.
Recommended Action
Review of the official Japanese posting and linked statement would help establish the events described, the statement's scope, and any clinical recommendations.